Close Menu

hepatitis

Tasso, a two-year-old startup focused on point-of-care, blood-based diagnostics, has been awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health to develop a sample preparation and stabilization device for use with HIV viral load quantif

Arrowhead Research this week announced that it has completed enrollment in a phase I trial of its siRNA-based hepatitis B treatment ARC-520, and that available data indicate that the compound is safe to advance into a planned phase IIa study.

Arrowhead Research’s top official this week announced that the company has shifted its research and development focus entirely onto RNAi drugs enabled by its dynamic polyconjugate, or DPC, delivery technology.

Arrowhead Research this week announced that it has begun dosing patients in a phase I study of its siRNA-based hepatitis B treatment ARC-520.

Life Technologies announced this week that it has signed a licensing agreement giving Suzhou Ribo Life Sciences the exclusive rights to use its Invivofectamine Rx delivery technology in the development and manufacturing of siRNA therapeutics in China.

Arrowhead Research said this week that it has filed an application with Australian regulators to begin phase I testing of its hepatitis B treatment ARC-520.

Veritas Bio, a biotechnology holding company established by two co-founders of expressed RNAi firm Nucleonics, said this week that the US Patent and Trademark Office has issued a notice of allowance on a patent application covering a novel liver-directed RNAi delivery technology.

Arrowhead Research said this week that its preclinical hepatitis B treatment ARC-520 was found to trigger a greater than 90 percent reduction in circulating HBV DNA in a chimpanzee chronically infected with the virus.

Shares of Benitec Biopharma resumed trading on the Australian Stock Exchange this week after the company announced that it had closed a A$800,000 ($821,760) private placement that it said would give it resources enough to fund a clinical trial of its recently reacquired hepatitis

Arrowhead Research this week published preclinical data demonstrating that its lead hepatitis B drug candidate, dubbed ARC-520, could silence the hepatitis B virus in rodents for up to one month after a single dose.

Pages

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.